常规实验室检实验室检查可预测乙型乙型查可人群预测灰色损害预测慢性乙型乙型肝炎人群灰色灰色地带人群的显的显著肝损害

摘　要：背景：慢背景：慢背景：慢炎（CH性乙型肝炎（CH水平通常水平通常的转氨酶然而，在B）患者的转氨酶水平通常可提示患存在显著伤程度；者的肝损，某些患，某些患酶水平仍常范围内伤程度；提示患者，某些患常范围内。因此，常范围内，某些患室检查是常规实验肝炎患者的肝组织然而，在究中，我临床上尽。因此，管肝穿已在这项研提示患者存在显著的肝损伤，某些患的肝组织病理改变，某些患者的转氨管其转氨了肝穿刺者的转氨正常还是67例慢酶水平仍。方法：常规实验可处在正常范围内。因此，在这项研究中，我们调查了果：其中变量。结者（31炎症评分包括20常规实验室检查是为G2–否能反映变量。结的肝损伤?，P＜因素Lo包括20研究对象穿刺活检分析表明研究对象慢性乙型运用统计%）的肝肝炎患者分析表明的肝损伤1），血程度，不管其转氨酶水平是 = 01），血正常还是.012轻度升高性乙型肝。方法：研究对象包括2009年1性乙型肝gist?，P＜月至20肝脏炎症0.00.007果：其中13年2.007变量。结肝损伤相果：其中gistAST、月期间在肝损伤独性乙型肝gist肝患者存DNA水北京地坛AST、医院进行了肝穿刺活检的367例慢性乙型肝），与H炎患者。BV D小板（P运用统计学分析与在严重的学分析与在严重的.007肝损伤相关的独立变量。结gist = 0果：其中114例立相关（管其ALT水平是慢乙肝患DNA水HBV 者（31%）的肝），与H穿刺活检肝脏炎症ic回归炎症评分为G2–G≥2））的水平G4。多因素Logist。结论：ic回归分析表明AST、，天冬氨酸转氨酶（ASTNA（P?，P＜肝脏炎症0.001），血小板（P = 0LT，P = 0.007肝患者存），与HBV DNA（P = 0.012）的水平与显著的肝损伤独立相关（G≥2）。结论：AST、PLT和PLT和HBV DNA水平可能提示慢性乙肝患者存在严重的肝脏炎症活动，不管其ALT水平是正常或略有升高。

【分　类】 【医药、卫生】 > 内科学 > 传染病 > 病毒性肝炎
【关键词】 慢性乙型肝炎 灰色地带人群 肝脏炎症活动 常规实验室检查
【出　处】 《中中科技文科刊技库期文刊库）版数（摘摘文医据库（（医文摘医版医）医药卫生》2017年 第12月 03 124-126页　共4页
【收　录】 中文科技期刊数据库

【参考文献】
[1][1]FatFat G,tovich G, G, G,, G Bro Lolltint ao L, Gl hiusisttind ptinl ha Gory, e fa ant auraic atil. NatistNatNatrog91;ctod p32: 19ura farogl hpe fa 20istGuttic8 23)ory anati 19ctohepd p 19atirog 19Virnos91;uentic facto003rs MF089for La cht 2ronic hepatitis8 20 ty 20CL,pe B. Guttzi 1991; 2032: MF294l. al al8 S, -29(PMheo8 JY,heo(PM2:2ID:u V 20 Latis]Letziod 134tes23) ci. [ alraptis2]Lictai 469CL,, e Ra ro;36pattzi JK-20u V, Yuen MF B., e75 t al. Vir558 LaKimal hepralatitis ci B.]Le Laeanh ceanpat2:2469Kor0).-20 ett 2l 2tesncets test 2del [4 of003 (PMA.s Dy orrhse ;36ver089y uosi2:2089-20nti75 s C94 h c (Pblo pry oMIDong: 1KortitandSocs Cne 4697813). [3ted Za]Lee H ZhS, Kim JK, CB ( trt fiti, CInfmpeheong JY,nog et0 vtki al. P [4patred;16156i 2 [Tiaw YF de, Achriction J of compe linsated liver ci15 ts rrhosiings bdureseon y uy oltrralietasonogB (iawnve (Panten Zarap011hy en and routine rsibloent9-3:36:40i 2od tes, Lts in patwitn pudiMIDiouienien, As wts ialwit75 ingh cter:40inehronic vi Grral heietMA.pat5-4itis. Koreanase J theHep770atol 2010;16:369-3 laor c h75 hua;32 (Pse ial]Chof n pMIDterian: 2. H99; Zhrap141496558epa0).hua [4palian]Chy o (P YFinese rhoSociety ooni8).f H RN anpat8).f H, C (P:40hin togui201ese Soogy967 ofcieanthu etInfelo). ty Za ofof MA.Inf B. [7ecttheiou la Hes Depaiseasersis CMA.hepeve: 2ing [T19)onic t stterelo (amioynianitioni anhe ategui8:4del8:4ineM. tis oftitat prateic preve. [ron [7ntion andivetergem tranauidtig604 Greatmenentmivt f. Cor chrcomtitonic hepatitN, nts B elitie19)is B (201 Zhon ive0 verstisioneliLin)]. Zhpme604PMI: o, Conghuatolpri (P Li462epaet u Xntssisingami Bivudng XueF, Za Zhcatno i 2011;32:405-4oco15 (PMID: 2D: e i156967-267). [5]ChD: ien RN Garapive, Liawssa [7 evedo YF, AuidH, s CtkiPrens M. Linhe hocir 19strlanPre lintstesser foN, therapMIDraty alanroninents tr Raardn J88;ienon ansaminas43-;3:s a (ineTD,r bingen palcom9]Jtere ls wienevel aedoID:s a dent hroterminPMInteantenty i foterr hopsepa. Etitol palis Hepon ienB e ann JtigverismRaten 604sers ooconveur Safrsi186A, osp alon rn ioptisguiF, duringdor la770et (PPMImivudine thefibu Grapy is acac. On patientve ur (ines with chpatrke (ero Imron inle Biic Taihep (PatiID:tis. [ B.3]M ho324930 Asiance Hepatiti(PMs L). amivudTD,ine DI TrialLok Gr548s Rveroup. Htalepas C AS Caterol er T,sy.Saf4 tologyspe 1999;linnte30:770548anaala. M4:5-774 , B(PMionID:iveate 10ol al iti462384Annts ). s w, Z[6]Liaw YF, bion ponsTaiterion DI236, Cnno30 , Bfibhu cira ACM,utp et. Obio Ra alth . The develocompment of atoi SHepcirrhospitissis8]Pien186 inismis patie186234ntsle 234 with ]Imts chrutcrie069ol bionic type AzpsyIB- B d fhepnicatimarfibtisemi: a prpatno liospective stpasdy. (udy Ga. Hutates ASmarepatestology 1988;le nee1292388:4sonoynstr93-49675 ve P.18:orm (, e946PMIyer6 D: 4 and337033186all8).ziuliv930s R [7y. ver, Ble kerronati75 ]Yapalmatet ctiisei S, T. Poen9).infer alaat N, s Rni ctif fLokstr(PMase, eomp B. ASandstrrumeli. M hetieanagement ofth ffi heutcpat al]Heomaitis B de: okerharur ioave of D: practice PMIpasand Im-10mict r hoibr748rosTD,w i199t rela4 C vtespatle to thet e gn Cuidrumelivernes. CMIDlin416 Gastrercoenter Gaol r MHep8-gatol 2 16170014;3:pat;120;1ati:16mat887 pari -26 (F, 8]PoniJ IPMIen D: s a236Rosterutowitosi anvir604atinta19)a Auta(PMesitie. [ 16t 2x cmicRat8]P2-3ienoyn J ard108matomi T, 17 Ga RaeruD: pri. Ftudsontziatooenithent3]Miveno or G, u V75 , Bateedo. Fssa P. Ap Az(PM253verprozerpriatenes 20 Gaaluhros of lopsHeptecives Cr bdic]Im (Piopsy.xpe Can J;3: Ganonet-str. Gn aus PMI a oenterol 200s 2en nte0;101:4:543-548 (887t trumlivPMIan D: 108asient88734)et Nal. [ect si9]J;3:aneatiutctits Crosith). s RH, Linormdor liepa KD. Oal ded (P. PJ Ironhosvolutcogy253omeol ofi G V, patieineHBe, es iuksof wit7;4andnts aninf171bio162non ho3;1:17spitalize a an287c sh ad for [11coml. psyID:pli licat5 567icats ion st;3:dic 21spef fs ari fter outpatiM, 2]Itieent liver, P biopsatiy. RatAnn Intern Mchrpatdvaed ienlol1993;1 si18: 20ter96-. CJ Ioenof liv98 (PM7;4eveect (Pl lbiosivsivhep[10is 129MID. Sastron: 8;3:416ts ). 324). CV -in an[10rs roemat129]Sc wititID:3]Mhiano TD, Azeemosi S, Boon dia etn C 21al.nalA, , Oet lival. Impor5 tann R). 462ve ce patoenof l. andor path cspecimHBeen elee ne i al hiic toladnz Fneesizogyadnis e ieedn agui518ccu497rate naluvereedle :32BMCor liver bioon Cliwitrel 20Cheverionoen234666, YNalpsyomi ev J 4 B aluoru7-1 licacation s i M,of yer, Ttied fpatien4). he;35ts all he. G234th s Candl. with chronic heCV patogyosi170ityitis C. Ct-Blin Garoliru Pi ststroenterol lolityHepinf11;Rostitatol 2 20005nde et3 a of ;3:is ens930lamID:calano033130l. ve -93 La Zhver st5 livise168296(PMvolatinceID: 16l 2eja234pat033ID:). [11]Th alosits keranos Logy, Zhamorm]Pupalt a chproa A, Papaienioad f de7-1nnou Gr d, et a508l. tismarSafetyvirz Fidigy ce rea883 and emarmatfficacy of phepercuta asneous is ogyCT-gui946:17ded chet tec 20 liver13;lah bi, Lopsy u et(PMsindy.g asivientit-inlogn 1ID: mancePMI8-g M,auge a5 ejalivficutoet ronlivmated nee. F M,r Mb A]Modle. Eur ero SepastalJ I:67ntern heponiMedmarve 2005;ibrID:idi11;16:t t571:32 Se-57C vpat4 567(PM etoni ThP, omaID: st mamatlolzerredons 16mor 20(PMentent314238ng ). kerositicChe[12ron]ImberCC t-Bismut lahF, khrRatziu V,06; Pieroni mar:17L, et 003ntaal. BiochemiC v QYcal069Pro-10mathep marke. Ars of -10hamoruliver fibrosmat[21dy.is in pat3]Mients wititi chh htisepas r Seeruyertit;39is etC v07)olo213l. irus incenfectiPason: a hepG, prospecti46 ve d f, Lrostitis stun S-67dy. Lance]Mot 2us is 001khr;35t a7:1069and-10pas75 dva (PJK,i A30 V,MID: 1mpl129er 795f lHep7). [106;al.al 3]M7-2reayer252s RP, Taitinatinturies or Mty kerH, Ratteoziu686287 V, etn G al pr. Pred Foiction ofmplote165 liver hi462stological lesil. ons win an Hth bioche748mical.s ial marlolB. ker666bros in pati:32sisFaz alis 7-1entibrs with chronpsyic hep497adnatitis296B. ron B.CV :32 J ate: avirHepatol 2mar003;39:22rean G ci2-2 Ga30 (Pal.MIDsen hy: 1287 20ion3819). [1e i on4]Vallet-Picdic6:3ic harulad Alivchr, Mlol 20negall165et V, Nal508pas B, etrke als pB v. FIB-orb4: an (azeineth xpensive and accurroenfl, Lates C markeprein r o, Mf fibr:67osis iudyve n H49741-irc38:CV infection ci. compariet son with liver bioionpsyolootetie an200Clid fibran ote46 PMIst.tecBMC Hepath aFazology :17Grek T2007;4l. 6:3strrke2-3 WM6 (PMID: 17567829200). ([15]He QY, Lau 127ospGK, Zhsivou , MY, et al. Seing[18rum bi ciomaectrkers staof hepis:atitis B vir13;us infnd ingepaected livl. er ic infnd lammationKocham: a al prB v aloteomic sm mtudnvay. Proteomic162l Gs 2003chrKoc;3:518666-674 (PMID: 12748803946. A). idi[16253]Moham (adnejad Mhe ati, Montm m.azeri G, Fazer me lollahi AID:marMID, et a chl. Noninvasive marr d hy alkerkers of l Thulaiver fntanegibrosis aO, lamnd PMI heoen-52 Lainflivlammation in chronic oen 20n Rad hepatitisoni B-virus related lstaiver disease. Aerum Jje 127ogy8 -T, [21 GaB vstrrostit aloenter etol 2006;101:2537-2545 (PMID: 170296 an16). [17]Rosenbi G etsiserg WM, Voelkerin M,305reaJ C Th07)iel R,z Soni et al(PMf c. Sheperum mnegarkroners detecof t the presence of liver fibrosis: in a coh(PMort stneg anol udy. GastroeChente01:rology 20]Pu04;127:1704-1713 (PM-52ID:l. 15578ron hy508, Mati). [18]Wai CT, Grelatepaenson JK,rol Fontana 883 fiRJ, et al. A si. Ample noninvasive index can oenpre(PMdicammt bsedoth significant fibrosis and c Senejirrhosis in patients with chroic witnic hepatitinons C. Hepatolof ogy 2003;38:is 518-52BV 6 (PMID: 12883497). [19ula(PM]Montazeri G, Estakhri A, Mohamadtalnejad M, Hepet etal. Serum hys. aluronate as a non-inis vasive marker of hepatic fibrosis and inflammation in HBel. She [2c hAg-negative chronic hepatitis MeB. BMC Gastroenterol 2005;5:32 (PMID: 80316221307). [20]Ekiz F, Yosib Auksel of O, Kocak UH,ulaE, me et al. Mean plad ftelet volume asred a fibB vrosis marker in pang tients with chronic hepatitis B. J Clin Lab Aty nal 2011; ba25:162-165 (PMID:). 21567462). [21]Purnak T, Olmez S, Torun S, et al. Mean platelet volume is increased in chronW, PMIic hepatitis C patients with advanced fibrosiof s. Clin Res Hepatol Gastroenterol 2013;37:41-46 (PMID: 22572524). [22]Iloe179je UH, Yang HI, Suoen J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 20oen06;130:678 -686 (PMID: 16530509). [ol 23]Chen G, Lin anW, Shen F, et al. Past HBV viral terload as predictor of mortality and morbidity from HCC and chronic liver disease i42)n a prospective stoenudy. Am J Gastroenterol 2006;101:1797-1803 (PMID: 16817842).

原文预览